Cited by 379Bone health and osteoporosis researchBone health and treatmentsBone Metabolism and Diseases

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

Open access

Boonen, Steven, Reginster, Jean-Yves, Kaufman, Jean-Marc, Lippuner, Kurt, Zanchetta, Jose, Langdahl, Bente, Rizzoli, Rene, Lipschitz, Stanley, Dimai, Hans Peter, Witvrouw, Richard, Eriksen, Erik, Brixen, Kim, Russo, Luis, Claessens, Frank, Papanastasiou, Philemon, Antunez, Oscar, Su, Guoqin, Bucci-Rechtweg, Christina, Hruska, Josef, Incera, Elodie, Vanderschueren, Dirk, Orwoll, Eric·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1204061

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis. METHODS: In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1199 men with primary or hypogonadism-associated osteoporosis who were 50 to 85 years of age to receive an intravenous infusion of zoledronic acid (5 mg) or placebo at baseline and at 12 months. Participants received daily calcium and vitamin D supplementation. The primary end point was the proportion of participants with one or more new morphometric vertebral fractures over a period of 24 months. RESULTS: The rate of any new morphometric vertebral fracture was 1.6% in the zoledronic acid group and 4.9% in the placebo group over the 24-month period, representing a 67% risk reduction with zoledronic acid (relative risk, 0.33; 95% confidence interval, 0.16 to 0.70; P=0.002). As compared with men who received placebo, men who received zoledronic acid had fewer moderate-to-severe vertebral fractures (P=0.03) and less height loss (P=0.002). Fewer participants who received zoledronic acid had clinical vertebral or nonvertebral fractures, although this difference did not reach significance because of the small number of fractures. Bone mineral density was higher and bone-turnover markers were lower in the men who received zoledronic acid (P<0.05 for both comparisons). Results were similar in men with low serum levels of total testosterone. The zoledronic acid and placebo groups did not differ significantly with respect to the incidence of death (2.6% and 2.9%, respectively) or serious adverse events (25.3% and 25.2%). CONCLUSIONS: Zoledronic acid treatment was associated with a significantly reduced risk of vertebral fracture among men with osteoporosis. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00439647.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1204061

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,822
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
Johnell, O., & Kanis, J. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0172-4 · Cited by 4,770
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citation
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citation
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003
Self-citation
Mortality after all major types of osteoporotic fracture in men and women: an observational study
Nguyen, T. V., Schneider, D. L., Sambrook, P. N., & Eisman, J. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09075-8 · Cited by 1,926
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580

Flagged first, then by citations

Show all 30 references

Sorted by citations

Items 101–200 of 379

Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis
Chen, L., Zhou, Z., Li, Y., Ning, G., Zhang, T., Zhang, D., & Feng, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128032 · Cited by 31
Odds ratio vs risk ratio in randomized controlled trials
Balasubramanian, H., Ananthan, A., Rao, S. C., & Patole, S. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1022494 · Cited by 32
RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients
Kachnic, L. A., Pugh, S. L., Tai, P., Smith, M. R., Gore, E., Shah, A. B., Martin, A.-G., Kim, H. E., Nabid, A., & Lawton, C. A. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.35 · Cited by 31
Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials
Chen, L., Wang, G., Zheng, F., Zhao, H., & Li, H. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3148-4 · Cited by 31
Clinical practice guidelines for postmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014)
González-Macı́as, J., del Pino‐Montes, J., Olmos, J. M., & Nogués, X. (2015) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2015.08.005 · Cited by 31
Pharmacological, Nutritional, and Rehabilitative Interventions to Improve the Complex Management of Osteoporosis in Patients with Chronic Obstructive Pulmonary Disease: A Narrative Review
Alessandro de, S. I. R. E., Lippi, L., Aprile, V., Calafiore, D., Folli, A., D’Abrosca, F., Moalli, S., Lucchi, M., Ammendolia, A., & Invernizzi, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101626 · Cited by 31
Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of prospective cohort study
Ensrud, K. E., Taylor, B. C., Peters, K. W., Gourlay, M. L., Donaldson, M. G., Leslie, W. D., Blackwell, T., Fink, H. A., ORWOLL, E. S., Schousboe, J. T., et al. (2014) · BMJ · doi:10.1136/bmj.g4120 · Cited by 30
Denosumab: A cost-effective alternative for older men with osteoporosis from a Swedish payer perspective
Parthan, A., Kruse, M., Agodoa, I., Silverman, S. L., & ORWOLL, E. S. (2013) · Bone · doi:10.1016/j.bone.2013.11.002 · Cited by 29
Follow-up Bone Mineral Density Testing: 2023 Official Positions of the International Society for Clinical Densitometry
Gani, L. U., Sritara, C., Blank, R. D., Chen, W., Gilmour, J., Dhaliwal, R., & Gill, R. S. (2023) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2023.101440 · Cited by 34
Current and future treatments of osteoporosis in men
Kaufman, J., Lapauw, B., & Goemaere, S. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.09.002 · Cited by 28
Percutaneous kyphoplasty combined with zoledronic acid infusion in the treatment of osteoporotic thoracolumbar fractures in the elderly
Shi, C., Zhang, M., Cheng, A.-Y., & Huang, Z. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s146871 · Cited by 28
Management of osteoporosis in older men
Kaufman, J. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01845-8 · Cited by 31
Male osteoporosis-what are the causes, diagnostic challenges, and management
Björnsdóttir, S., Clarke, B. L., Mannstadt, M., & Langdahl, B. L. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101766 · Cited by 28
Bone Density Screening and Re-screening in Postmenopausal Women and Older Men
Gourlay, M. L., Overman, R. A., & Ensrud, K. E. (2015) · Current Osteoporosis Reports · doi:10.1007/s11914-015-0289-5 · Cited by 28
Severe Anorexia Nervosa in Males: Clinical Presentations and Medical Treatment
Sabel, A. L., Rosen, E., & Mehler, P. S. (2014) · Eating Disorders · doi:10.1080/10640266.2014.890459 · Cited by 28
Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow?
Farach‐Carson, M. C., Lin, S.-H., Nalty, T., & Satcher, R. L. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00163 · Cited by 28
Osteoporose – Definition, Risikoerfassung, Diagnose, Prävention und Therapie (Update 2024)
Dimai, H. P., Muschitz, C., Amrein, K., Bauer, R., Cejka, D., Gasser, R. W., Gruber, R., Haschka, J., Hasenoehrl, T., Kainberger, F. M., et al. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02441-2 · Cited by 28
Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses
Zhou, J., Wang, T., Zhao, X., Miller, D. R., & Zhai, S. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0030-6 · Cited by 27
Effect of Traditional Chinese Medicine Product, QiangGuYin, on Bone Mineral Density and Bone Turnover in Chinese Postmenopausal Osteoporosis
Shi, Z.-Y., Zhang, X.-G., Li, C., Liu, K., Liang, B., & Shi, X.-L. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/6062707 · Cited by 27
Current and future treatments of secondary osteoporosis
Soriano, R., Herrera, S., Nogués, X., & Díez‐Pérez, A. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.09.004 · Cited by 26
Cardiac adverse events in bisphosphonate and teriparatide users: An international pharmacovigilance study
Rodríguez, A. J., Nerlekar, N., & Ebeling, P. R. (2022) · Bone · doi:10.1016/j.bone.2022.116647 · Cited by 25
Osteoporosis in men
Misiorowski, W. (2017) · Menopause Review/Przegląd Menopauzalny · doi:10.5114/pm.2017.68596 · Cited by 25
Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study
Shiraki, M., Kuroda, T., Takeuchi, Y., Sugimoto, T., Tanaka, S., Suzuki, H., Hiraishi, K., & Nakamura, T. (2021) · Calcified Tissue International · doi:10.1007/s00223-021-00884-7 · Cited by 24
Naringin protects against bone loss in steroid-treated inflammatory bowel disease in a rat model
Li, C., Zhang, J., Lv, F., Ge, X., & Li, G. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.05.011 · Cited by 23
Treatment of Osteoporosis, with a Focus on 2 Monoclonal Antibodies
Chang, B., Quan, Q., Li, Y., Qiu, H., Jiang, P., & Gu, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.912309 · Cited by 23
Does Routine Anti-Osteoporosis Medication Lower the Risk of Fractures in Male Subjects? An Updated Systematic Review With Meta-Analysis of Clinical Trials
Zeng, L., Pan, B.-Q., Liang, G.-H., Luo, M., Cao, Y., Guo, D., Chen, H., Pan, J., Huang, H., Liu, Q., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00882 · Cited by 23
Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials
Wang, C. (2016) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000415 · Cited by 23
Guidelines of the Brazilian Society of Rheumatology for the diagnosis and treatment of osteoporosis in men
Loures, M. A. A. D. R., Zerbini, C. A. F., Danowski, J. S., Pereira, R. M. R., Moreira, C., de Paula, A. P., Castro, C. H. D. M., Szejnfeld, V. L., de Mendonça, L. M. C., Radominiski, S. C., et al. (2017) · Revista Brasileira de Reumatologia (English Edition) · doi:10.1016/j.rbre.2017.07.003 · Cited by 26
OFELIA: Prevalence of Osteoporosis in Fragility Fracture Patients
Tei, R., Ramlau‐Hansen, C. H., Plana‐Ripoll, O., Brink, O., & Langdahl, B. L. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0476-3 · Cited by 22
Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis
Binkley, N., ORWOLL, E. S., Chapurlat, R. D., Langdahl, B. L., Scott, B. B., Giezek, H., & Santora, A. C. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05701-9 · Cited by 22
Osteoporosis in men
Korpi-Steiner, N. L., Milhorn, D. M., & Hammett‐Stabler, C. A. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.03.026 · Cited by 22
Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions
Ruža, I., Mirfakhraee, S., ORWOLL, E. S., & Gruntmanis, U. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x13485829 · Cited by 23
Understanding estimands
Gogtay, N. J., Ranganathan, P., & Aggarwal, R. (2021) · Perspectives in Clinical Research · doi:10.4103/picr.picr_384_20 · Cited by 21
Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence
Sim, I., & Ebeling, P. R. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x13500861 · Cited by 22
Novel osteoporosis targets
Ohlsson, C. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.252 · Cited by 21
Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least 11 Years in HIV-Infected Men
Bolland, M. J., Horne, A. M., Briggs, S. E., Thomas, M. G., Reid, I. R., Gamble, G. D., & Grey, A. B. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3712 · Cited by 21
Updates on Osteoporosis in Men
Diab, D. L., & Watts, N. B. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.03.001 · Cited by 21
Osteoporosis in men: recent progress
Adler, R. A. (2013) · Endocrine · doi:10.1007/s12020-013-9880-7 · Cited by 21
Status of drug development for the prevention and treatment of osteoporosis
Schwarz, P., Jørgensen, N. R., & Abrahamsen, B. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.884067 · Cited by 20
Bone health in hypogonadal men
Irwig, M. S. (2014) · Current Opinion in Urology · doi:10.1097/mou.0000000000000104 · Cited by 20
Evaluation of predictive factors of vertebral compression fracture after conventional palliative radiotherapy for spinal metastasis from colorectal cancer
Lee, J., Rhee, W. J., Chang, J. S., Chang, S. K., & Koom, W. S. (2017) · Journal of Neurosurgery Spine · doi:10.3171/2017.6.spine17282 · Cited by 20
Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis
Shiraki, M., Tanaka, S., Suzuki, H., Ueda, S., & Nakamura, T. (2016) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-016-0806-3 · Cited by 20
A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis
Belaya, Z. E., Rozhinskaya, L. Y., Dedov, I. I., Drapkina, O. M., Fadeev, V. V., Golounina, O. O., Lesnyak, O. M., Mamedova, E., Mel'nichenko, G. A., Petraikin, A. V., et al. (2023) · Osteoporosis International · doi:10.1007/s00198-022-06667-6 · Cited by 24
Time to Osteoporosis and Major Fracture in Older Men
Gourlay, M. L., Overman, R. A., Fine, J. P., Filteau, G., Cawthon, P. M., Schousboe, J. T., ORWOLL, E. S., Wilt, T. J., Nguyen, T. V., Lane, N. E., et al. (2016) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.11.015 · Cited by 19
The impact of preventive measures on the burden of femoral fractures – a modelling approach to estimating the impact of fall prevention exercises and oral bisphosphonate treatment for the years 2014 and 2025
Benzinger, P., Becker, C., Todd, C. J., Bleibler, F., Rothenbacher, D., König, H., & Rapp, K. (2016) · BMC Geriatrics · doi:10.1186/s12877-016-0247-9 · Cited by 19
Updated systematic review
Raftery, J. P., Hanney, S. R., Greenhalgh, T., Glover, M. J., & Blatch-Jones, A. (2016) · Cited by 17
Osteoporosis and Low Bone Mineral Density in Men with Testosterone Deficiency Syndrome
Gaffney, C., Pagano, M. J., Kuker, A. P., Stember, D. S., & Stahl, P. J. (2015) · Sexual Medicine Reviews · doi:10.1002/smrj.63 · Cited by 18
Male hypogonadism and skeletal health
Irwig, M. S. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/01.med.0000436185.36717.76 · Cited by 18
Efficacy of zoledronic acid in treatment of osteoporosis in men and women-a meta-analysis.
Liu, M., Guo, L., Pei, Y., Li, N., Jin, M., Ma, L., Liu, Y., Sun, B., & Li, C. (2015) · Europe PMC (PubMed Central) · Cited by 18
Recommandations françaises de la prise en charge et du traitement de l’ostéoporose masculine
Bouvard, B., Briot, K., Legrand, É., Blain, H., Breuil, V., Chapurlat, R. D., Duquenne, M., Guggenbuhl, P., Lespessailles, É., Thomas, T., et al. (2021) · Revue du Rhumatisme · doi:10.1016/j.rhum.2021.02.024 · Cited by 18
Percutaneous kyphoplasty combined with zoledronic acid for the treatment of primary osteoporotic vertebral compression fracture: a prospective, multicenter study
Liu, K., Tan, G., Sun, W., Lü, Q., Tang, J., & Yu, D. (2022) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-022-04557-4 · Cited by 18
Cardiovascular safety of zoledronic acid in the treatment of primary osteoporosis: A meta-analysis and systematic review
Liu, S., Tan, Y., Huang, W., Luo, H., Pan, B., & Wu, S. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152304 · Cited by 17
Zebrafish mutants reveal unexpected role of Lrp5 in osteoclast regulation
Khrystoforova, I., Shochat-Carvalho, C., Harari, R., Henke, K., Woronowicz, K. C., Harris, M. P., & Karasik, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.985304 · Cited by 18
A meta-analysis of bisphosphonates for periprosthetic bone loss after total joint arthroplasty
Zhu, L., Zheng, W., Zhao, F., Guo, Y., Meng, B.-Y., Guo, K., & Liu, H.-T. (2013) · Journal of Orthopaedic Science · doi:10.1007/s00776-013-0411-4 · Cited by 17
Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study
Doria, C. (2016) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2016.13.3.195 · Cited by 18
Osteoporosis Update From the 2012 Santa Fe Bone Symposium
Lewiecki, E. M., Adler, R. A., Bilezikian, J. P., Bouxsein, M., Marcus, R., McClung, M. R., Miller, P. D., Tanner, S. B., & Randall, S. (2013) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2013.01.001 · Cited by 17
The Case for Bisphosphonate Use in Astronauts Flying Long-Duration Missions
Rosenthal, R. M., Schneider, V. S., Jones, J. A., & Sibonga, J. D. (2024) · Cells · doi:10.3390/cells13161337 · Cited by 17
Summary of the draft federal clinical guidelines for osteoporosis
Belaya, Z. E., Rozhinskaya, L. Y., Grebennikova, T. A., Kanis, J. А., Pigarova, E. A., Rodionova, S. S., Toroptsova, N. V., Nikitinskaya, O. A., Skripnikova, I. A., Drapkina, O. M., et al. (2021) · Osteoporosis and Bone Diseases · doi:10.14341/osteo12710 · Cited by 17
Suboptimal osteoporosis evaluation and treatment in older men with and without additional high-risk factors for fractures
Narla, R. R., Hirano, L. A., Lo, S. H. Y., Anawalt, B. D., Phelan, E. A., & Matsumoto, A. M. (2019) · Journal of Investigative Medicine · doi:10.1136/jim-2018-000907 · Cited by 15
Osteoporosis treatment prevents hip fracture similarly in both sexes: the FOCUS observational study
Keaveny, T. M., Adams, A. L., ORWOLL, E. S., Khosla, S., Siris, E. S., McClung, M. R., Bouxsein, M., Fatemi, S., Lee, D. C., & Kopperdahl, D. L. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae090 · Cited by 15
Durability and delayed treatment effects of zoledronic acid on bone loss after spinal cord injury: a randomized, controlled trial
Edwards, W. B., Haider, I. T., Simonian, N., Barroso, J., & Schnitzer, T. J. (2021) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4416 · Cited by 16
Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients
Makras, P., Petrikkos, P., Anastasilakis, A. D., Kolynou, A., Katsarou, A., Tsachouridou, Ο., Metallidis, S., & Yavropoulou, M. P. (2021) · Bone Reports · doi:10.1016/j.bonr.2021.101128 · Cited by 15
Diretrizes da Sociedade Brasileira de Reumatologia para diagnóstico e tratamento da osteoporose em homens
Loures, M. A. A. D. R., Zerbini, C. A. F., Danowski, J. S., Pereira, R. M. R., Moreira, C., de Paula, A. P., Castro, C. H. D. M., Szejnfeld, V. L., de Mendonça, L. M. C., Radominiski, S. C., et al. (2017) · Revista Brasileira de Reumatologia · doi:10.1016/j.rbr.2017.06.002 · Cited by 15
Time since last intravenous bisphosphonate and risk of osteonecrosis of the jaw in osteoporotic patients
Park, J. H., Kong, S. H., Lee, J., Oh, J., Lee, J.-R., Lee, H., & Kim, J. (2025) · Nature Communications · doi:10.1038/s41467-025-59718-x · Cited by 17
Efficacy of Antiresorptive Treatment in Osteoporotic Older Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Cedeño‐Veloz, B. A., Erviti, J., Gutiérrez‐Valencia, M., Leache, L., Saiz, L. C., García, A. M. R., Latorre, M. S., Ramírez‐Vélez, R., Izquierdo, M., & Martínez‐Velilla, N. (2022) · The journal of nutrition health & aging · doi:10.1007/s12603-022-1825-5 · Cited by 14
Do femoral fractures in adult patients with osteogenesis imperfecta imitate atypical femoral fractures? A case series
Andersen, J. D., Bünger, M., Rahbek, O., Hald, J. D., Harsløf, T., & Langdahl, B. L. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4769-1 · Cited by 14
Adjuvant pharmacological strategies for the musculoskeletal system during long‐term space missions
Thomasius, F. E., Pesta, D. H., & Rittweger, J. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15877 · Cited by 14
Ginsenoside Rb2 exhibits therapeutic value for male osteoporosis in orchiectomy mice by suppressing osteoclastogenesis and modulating NF-κB/MAPK signaling pathways
Ma, Y., Li, J., Mai, J., Guo, H., Ding, L., Li, J., Xiao, J., Li, M., Fang, W., Zhang, S., et al. (2024) · Food & Function · doi:10.1039/d3fo04334g · Cited by 13
Biochemical markers of bone turnover in osteoporosis
Szulc, P., Bauer, D. C., & Eastell, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00065-4 · Cited by 14
Short-term effects of COVID-19 on the risk of traumatic fractures in China cities
Lv, H., Zhang, X., Wang, J., Hou, Z., Wang, H., Li, C., Wang, W., Chen, W., & Zhang, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-10531-2 · Cited by 13
Comparison of three-dimensional printing for fabricating silk fibroin-blended scaffolds
Sun, K., Li, R., Li, H., Li, D., & Jiang, W. (2017) · International Journal of Polymeric Materials · doi:10.1080/00914037.2017.1354204 · Cited by 13
Primary osteoporosis in men: an unmet medical need
Mendoza, F. A., Roux, M. L., & Ahmed, I. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.10.003 · Cited by 13
Intravenous zoledronate for osteoporosis: less might be more
Grey, A. B. (2016) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x16650866 · Cited by 13
Can Bisphosphonate Therapy Reduce Overall Mortality in Patients With Osteoporosis? A Meta-analysis of Randomized Controlled Trials
Lan, Z., Lin, X., Xue, D., Yang, Y., Saad, M., & Jin, Q. (2024) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000003204 · Cited by 12
A Model of BMD Changes After Alendronate Discontinuation to Guide Postalendronate BMD Monitoring
McNabb, B., Vittinghoff, E., Eastell, R., Schwartz, A. V., Bauer, D. C., Ensrud, K. E., Barrett-Connor, E. L., & Black, D. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1193 · Cited by 12
Bone Material Strength Index as Measured by Impact Microindentation is Low in Patients with Primary Hyperparathyroidism
Schoeb, M., Winter, E. M., Sleddering, M. A., Lips, M. A., Schepers, A., Snel, M., & Appelman‐Dijkstra, N. M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab207 · Cited by 12
Risk of falls in patients with low bone mineral density
Möckel, L. (2020) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-020-01784-5 · Cited by 11
Surgeon Specialty Influences Referral Rate for Osteoporosis Management following Vertebral Compression Fractures
Daffner, S. D., Karnes, J. M., & Watkins, C. M. (2015) · Global Spine Journal · doi:10.1055/s-0035-1569057 · Cited by 11
Screening to prevent fragility fractures among adults 40 years and older in primary care: protocol for a systematic review
Gates, M., Pillay, J., Thériault, G., Limburg, H., Grad, R. M., Klarenbach, S. W., Korownyk, C. S., Reynolds, D. L., Riva, J. J., Thombs, B. D., et al. (2019) · Systematic Reviews · doi:10.1186/s13643-019-1094-5 · Cited by 12
Treatment Considerations for Severe Osteoporosis in Older Adults
See, H., Gowling, E., Boswell, E., Aggarwal, P., King, K., Smith, N., Lim, S. E. R., Baxter, M. A., & Patel, H. P. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01205-5 · Cited by 11
The effect of zoledronic acid on the fracture risk in men with osteoporosis
Spiegel, R., Nawroth, P. P., & Kasperk, C. H. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-013-0038-5 · Cited by 10
A review on osteoporosis in men
Stathopoulos, I., Ballas, E. G., Lampropoulou-Adamidou, K. I., & Trovas, G. (2014) · HORMONES · doi:10.14310/horm.2002.1550 · Cited by 10
Soluble interleukin 2 receptor is risk for sarcopenia in Men with high fracture risk
Ge, J., Zeng, J., Li, N., Ma, H., Zhao, Z., Sun, S., Jing, Y., Qian, C., Fei, Z., Qu, S., et al. (2022) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2022.10.017 · Cited by 10
Exploration of the Effect of mmu-miR-142-5p on Osteoblast and the Mechanism
Zhao, R., Zhu, Y., & Sun, B. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0193-0 · Cited by 10
The impact of acute-phase reaction on mortality and re-fracture after zoledronic acid in hospitalized elderly osteoporotic fracture patients
Lü, K., Wu, Y.-M., Shi, Q., Gong, Y.-Q., Zhang, T., & Li, C. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06803-w · Cited by 9
Medication-Related Osteonecrosis of the Jaws From Once Per Year Intravenous Zoledronic Acid (Reclast)
Lee, C. Y. S., & Suzuki, J. B. (2015) · Implant Dentistry · doi:10.1097/id.0000000000000227 · Cited by 9
SUMMARY OF CLINICAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS OF THE RUSSIAN ASSOCIATION OF ENDOCRINOLOGISTS
Mel'nichenko, G. A., Belaya, Z. E., Rozhinskaya, L. Y., Grebennikova, T. A., Pigarova, E. A., Toroptsova, N. V., Nikitinskaya, O. A., Farba, L. Y., Tarbaeva, N. V., Chernova, T. A., et al. (2016) · Osteoporosis and Bone Diseases · doi:10.14341/osteo2016328-36 · Cited by 9
Association of Bisphosphonate Therapy With Incident of Lower Extremity Fractures in Persons With Spinal Cord Injuries or Disorders
Carbone, L. D., González, B., Miskevics, S. A., Ray, C. E., Etingen, B., Guihan, M., Craven, B. C., George, V. T., & Weaver, F. M. (2020) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2019.12.010 · Cited by 9
Männliche Osteoporose
Farahmand, P., Spiegel, R., & Ringe, J. D. (2016) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-016-0078-2 · Cited by 9
Effects of Bisphosphonates on Bone of Osteoporotic Men With Different Androgen Levels: A Case-Control Study
Zhou, B., Hu, J., Sun, L., Wang, O., Jiang, Y., Xia, W., Xing, X., & Li, M. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.12.013 · Cited by 9
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis
Li, P., Wu, X., Li, Y., & Huang, J. (2022) · Clinical and investigative medicine · doi:10.25011/cim.v45i3.38875 · Cited by 9
Fracture Risk and Zoledronic Acid in Men with Osteoporosis
Boonen, S., & ORWOLL, E. S. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1214992 · Cited by 9
Zoledronic acid increases spine bone mass and prevents hip bone loss after bariatric surgery: a randomized placebo‐controlled study
Gam, S., Lysdahlgaard, S., Gram, B., Kusk, M. W., Hermann, A. P., Juhl, C. B., & Hansen, S. G. (2025) · Obesity · doi:10.1002/oby.24214 · Cited by 8
Osteoporosis in Men: an Overlooked Patient Population
Chou, S. H.-H. (2025) · Current Osteoporosis Reports · doi:10.1007/s11914-025-00907-4 · Cited by 9
Effectiveness and Safety of Zoledronic Acid in the Treatment of Osteoporosis
Hsieh, P.-C. (2016) · Orthopedics · doi:10.3928/01477447-20160201-02 · Cited by 8
May zoledronic acid have negative effects on cognition and muscle performance?
Bahşi, R., Atmış, V., Turgut, T., Sürmeli, D. M., Coşarderelioğlu, Ç., Öztorun, H. S., Yalçın, A., Aras, S., & Varlı, M. (2019) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-019-02086-5 · Cited by 8
Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders
Trajanoska, K., & Rivadeneira, F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.556610 · Cited by 8
Collecting data on fractures: a review of epidemiological studies on orthopaedic traumatology and the Chinese experience in large volume databases
Lv, H., Chen, W., Yao, M., Hou, Z., & Zhang, Y. (2022) · International Orthopaedics · doi:10.1007/s00264-022-05299-z · Cited by 8
Prediction of musculoskeletal pain after the first intravenous zoledronic acid injection in patients with primary osteoporosis: development and evaluation of a new nomogram
Zheng, X., Ye, J., Zhan, Q., Zhao, W., Liao, Z., Ye, X., & Qu, C. (2023) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-023-06965-y · Cited by 8
Early adverse events after the first administration of zoledronic acid in Japanese patients with osteoporosis
Takada, J., Iba, K., Yamamoto, O., Dohke, T., Saito, A., Yamamura, M., Takebayashi, T., Akatsuka, T., & Yamashita, T. (2021) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-021-01231-4 · Cited by 8

Authors: Boonen, S., Reginster, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., Eriksen, E., Brixen, K., Russo, L., Claessens, F., Papanastasiou, P., Antunez, O., Su, G., Bucci-Rechtweg, C., Hruska, J., Incera, E., Vanderschueren, D., & Orwoll, E.
Affiliations: KU Leuven (BE)
University of Liège (BE)
Ghent University (BE)
University of Bern (CH)
Aarhus University Hospital (DK)
Medical University of Graz (AT)
Ziekenhuis Oost-Limburg (BE)
University of Oslo (NO)
University of Southern Denmark (DK)
Novartis (Switzerland) (CH)
Oregon Health & Science University (US)
ORCID: Reginster, Jean-Yves
Kaufman, Jean-Marc
Lippuner, Kurt
Langdahl, Bente
Dimai, Hans Peter
Eriksen, Erik
Claessens, Frank
Bucci-Rechtweg, Christina
Incera, Elodie
Vanderschueren, Dirk
Orwoll, Eric
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-11
Volume: 367
Issue: 18
Pages: 1714-1723
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1204061
OpenAlex: W2123816368
Cited by: 359
References: 30
Citations by year: 2026: 17 · 2025: 24 · 2024: 23 · 2023: 21 · 2022: 25 · 2021: 25 · 2020: 26 · 2019: 24 · 2018: 30 · 2017: 21 · 2016: 28 · 2015: 23 · 2014: 29 · 2013: 36 · 2012: 5
FWCI: 32.02
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Archive ouverte UNIGE (University of Geneva) (publishedVersion)
Ghent University Academic Bibliography (Ghent University) (submittedVersion)
BORIS (University Library Bern) (submittedVersion, other-oa)
IRIS (submittedVersion)
Open Repository and Bibliography (University of Liège) (submittedVersion)
University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
Open Access CRIS of the University of Bern
Funders: U.S. Department of Justice
Amgen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Teva Pharmaceutical Industries
Danone
University of Bern
Union Chimique Belge
Daiichi-Sankyo
Novo Nordisk
Servier
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Oncology › Bone health and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords: zoledronic acid, male osteoporosis, vertebral fractures, fracture risk reduction, bisphosphonates, androgen deficiency, bone mineral density, bone turnover markers, height loss
MeSH terms: Zoledronic Acid, Aged, Aged, 80 and over, Analysis of Variance, Diphosphonates, Double-Blind Method, Humans, Hypogonadism, Imidazoles, Male, Middle Aged, Osteoporosis, Risk, Testosterone, Bone Density, Logistic Models, Spinal Fractures, Bone Density Conservation Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks